A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Prior treatment

• Received immunosuppressive medication within the last 14 days of initiating study treatment
• Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
  • Other protocol-defined inclusion/exclusion criteria apply

Other illness

• Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis

Other

• Known central nervous system (CNS) involvement with myeloma

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
  • For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:
• Documented diagnosis of multiple myeloma (MM) and measurable disease
• Documented disease progression during or after their last antimyeloma regimen
• Achieved a response (minimal response \[MR\] or better) to at least 1 prior treatment regimen